Biotheus is a clinical-stage biotech company focused on the discovery and development of biologics for oncology and inflammatory diseases.

Biotheus

Biotheus Inc. | 1,314 followers on LinkedIn. To Inspire Each Other and Create Effective Medicines for Humankind | Biotheus (普米斯生物技术) aims to discover and develop effective therapeutic biologics for patients with cancer and inflammatory disease. We believe in creative scientific and industrial/academic collaborations in order to reach this common goal.

Vice President Business Development & Licensing ex-China

Roland Meisel, Ph.D.

Executive Director, GM of Nantong Site

Bingyan He

Healthcare investment in Cowin Venture Capital

Jason (Hai) Jiang

Biotheus - BD Senior Manager

Yanli Du

Biotheus Inc.

We are thrilled to celebrate the grand opening of our biologics (DS/DP) manufacturing facility in Nantong 🎉. At this state-of-the-art facility, we have 3 x 2000L lines dedicated to supporting the global development of our pipeline. #Biologics #Manufacturing

Andy T.

Bispecific antibodies, a novel class of immunotherapies, are showing significant promise in oncology. These engineered antibodies can simultaneously bind to two different antigens, providing unique mechanisms of action. Hematological malignancies are the primary focus of bispecific antibody development. Fast forward to 2022–2023, and we witnessed a dynamic shift, with eight new bispecific approvals, primarily revolutionizing hematological cancer treatments. Nevertheless, numerous bispecific antibodies are under investigation for various solid tumors, including gastric, colorectal, ovarian, prostate, and Lung cancer. Immunocore , Innovent Biologics , Johnson & Johnson Innovative Medicine , Roche , Curonix , Genmab , AbbVie , Merus N.V. , Summit Therapeutics, Inc. , BioNTech SE , Affimed , Biotheus Inc. , Amgen , Regeneron , Qilu Pharmaceuticals , and others showcased their latest research and advancements in bispecific treatments at the American Society of Clinical Oncology (ASCO) 2024. Get an in-depth analysis of bispecific antibodies coverage from the ASCO 2024 conference at https://lnkd.in/gwDBMuqP

DelveInsight Business Research LLP

We have strengthened our partnership with Hansoh Pharmaceuticals on PM1080/HS-20117, a EGFR x cMET bispecific, for development of an ADC product. I would like to thank the team at Hansoh for believing in the potential of PM1080 and excited by their vision in the ADC space. Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Biotheus Inc.

Meet our senior team in San Francisco for JPM2024!

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 12, 2024 5:34 AM	1e88ba22
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 12, 2024 5:34 AM	d26267e3
crunchbase trigger	general	Nov 27, 2024 12:50 PM	b9c9a841
crunchbase profile	general
li profile	general	Nov 12, 2024 5:34 AM	34699707
translate crunchbase fundingrounds	general
peers	general	Nov 12, 2024 5:34 AM	ae16dd14
news basic	general	Nov 12, 2024 5:34 AM	ffb1be26
bundesanzeiger	filings
financials download nd	financials
private financials	financials

BIOT

COM:BIOTHEUS

Biotheus